Davies, M. J., van der Meer, P., Verma, S., Patel, S., Chinnakondepalli, K. M., Borlaug, B. A., Butler, J., Kitzman, D. W., Shah, S. J., Harring, S., Salsali, A., Rasmussen, S., von Lewinski, D., Abhayaratna, W., Petrie, M. C., Kosiborod, M. N., & STEP-HFpEF Trials Committees and Investigators. (2025). Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology, 13(3), 196–209. https://doi.org/10.1016/S2213-8587(24)00304-8
